Abstract
Abstract Background and Aims This study aimed to observe and evaluate the effect of bisoprolol in the improvement of HFpEF patient’s QoL. As we know, Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure in 2020 and half of the case classified as HFpEF. It is well known that someone who have been diagnosed with heart failure will have a poorer quality of life/QoL. β-blocker is a heart rate lowering agent with a potency to improve the patient’s clinical outcome, such as QoL. Methods and Results This study is a retrospective cohort following HFpEF patients who received bisoprolol and who did not received bisoprolol. The study participant selected by purposive sampling method, who meet inclusion and exclusion criteria. This research was analysed by SPSS 25 version. It used comparasion test and regresion test to determine differences in the effects of using bisoprolol and which combination was good for lowering the MLHFQ score. The result of comparison between bisoprolol grup and non-bisoprolol grup showed a significance value of 0.000 (p < 0.05). Meanwhile, if bisoprolol are combined with other drugs, only the combination of 2.5 mg bisoprolol with ACE-Inhibitor has a significant effect on QoL (p total score 0.007) Conclusion We conclude that the use of bisoprolol as combination therapy is usefull for management HFpEF, because it showed improvement in the HFpEF patient’s QoL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
